Expert panelists review new data on treatment and management of nmCRPC, mHSPC, and mCRPC and consider how these data may impact clinical practice.
March 3rd 2023
Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.
Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.
March 22nd 2023
Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.
Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.
March 29th 2023
Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
April 5th 2023
Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.
A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.
April 12th 2023
Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.
Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.
April 19th 2023
Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.
A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.
April 26th 2023
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.
May 3rd 2023
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
May 10th 2023
Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.
Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
May 17th 2023
Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).
Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.